SCHEMBL2621800

SCHEMBL2621800

CN1CCC(Oc2ccnc3ccc(Br)cc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 1/20 0.50
▸ HCRTR2 O43614 1/20 0.50
▸ HTT P42858 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ PIK3CD O00329 3/20 0.43
▸ PIK3CA P42336 3/20 0.43
▸ PIK3CB P42338 3/20 0.43
▸ PIK3CG P48736 3/20 0.43
▸ NCF1 P14598 1/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.42
▸ LRRK2 Q5S007 1/20 0.42
▸ PDPK1 O15530 2/20 0.40
▸ GAK O14976 1/20 0.39
▸ EPHB6 O15197 1/20 0.39
▸ RIPK2 O43353 1/20 0.39
▸ STK16 O75716 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ ACVR1 Q04771 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2621797 0.94 HCRTR1 (0.52) HCRTR1HCRTR2HTTMEN1POLB
SCHEMBL22392626 0.88 HCRTR1 (0.51) HCRTR1HCRTR2NCF1IRAK4GAK
SCHEMBL20074469 0.80 IDO1 (0.55) HCRTR1HCRTR2PIK3CDPIK3CAPIK3CB
SCHEMBL12850523 0.80 IRAK4 (0.65) HTTMEN1POLBKMT2APIK3CD
SCHEMBL2621811 0.79 EGFR (0.46) HCRTR1HCRTR2HTTMEN1POLB
SCHEMBL2621812 0.79 EGFR (0.46) HCRTR1HCRTR2HTTMEN1POLB
SCHEMBL19723307 0.79 EGFR (0.46) HCRTR1HCRTR2HTTMEN1POLB
SCHEMBL20292863 0.77 DYRK1A (0.58) HTTMEN1POLBKMT2ANCF1
SCHEMBL21723114 0.75 HCRTR1 (0.45) HCRTR1HCRTR2PIK3CDLRRK2
SCHEMBL2621794 0.75 HTR1B (0.48) HTTMEN1POLBKMT2AGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560967-B1 Heterocyclic carboxylic acid amides as PDK1 inihibitors BOEHRINGER INGELHEIM INT (DE) 2017-12-20 — — EP disclosed
US-8575203-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-05 — — US disclosed
US-8575203-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-05 — — US disclosed
US-20120094976-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 — — US disclosed
US-20120094976-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 — — US disclosed
WO-2011131741-A1 HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094976-A1 NEW CHEMICAL COMPOUNDS CCNB1, MKI67, CCNA1 HCRTR1 1385/4885HCRTR2 2736/4885HTT 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback